Top

International Journal of Colorectal Disease

Published in:

01-12-2023 | Rectal Cancer | RESEARCH

Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer

Authors: Chun-Kai Liao, Ya-Ting Kuo, Yu-Jen Hsu, Yih-Jong Chern, Yen-Lin Yu, Yueh-Chen Lin, Pao-Shiu Hsieh, Jy-Ming Chiang, Chien‐Yuh Yeh, Jeng-Fu You

Published in: International Journal of Colorectal Disease | Issue 1/2023

Abstract

Purpose

We analyzed the effectiveness, safety, and mid-term oncological outcomes of short-course radiotherapy (SCRT) and oxaliplatin-based consolidation chemotherapy in patients with locally advanced rectal cancer (LARC).

Methods

We retrospectively evaluated 64 patients with LARC who underwent SCRT and tegafox (tegafur–uracil/leucovorin plus oxaliplatin) or mFOLFOX-6 (5-fluorouracil, leucovorin, and oxaliplatin) consolidation chemotherapy before surgery between January 2015 and December 2020. Tumor response, patient compliance, toxicity, surgical outcomes, overall survival (OS), and disease-free survival (DFS) were analyzed.

Results

Sixty-four patients with a mean age of 58.67 years (44 males) were included; 48 (75%) had tumors within 5 cm of the anal verge. Additionally, 93.8% of the patients underwent at least 2 months of chemotherapy, and three required dose reduction. Grade III toxicity occurred in 2 patients, and 10 had a clinical complete response and opted for non-operative management. One patient experienced tumor progression and underwent further treatment without surgery. Among the 53 patients who underwent surgery, 51 (96.2%) had sphincter preservation, 3 had Clavien–Dindo grade III complications, and no mortality occurred. The complete response rate for the entire cohort was 23.4%. Moreover, 47 patients (74.6%) had a neoadjuvant rectal score of < 16 after treatment. After a median follow-up time of 32.01 months, 6 (9.3%) had local recurrence, and 17 (26.6%) had distant metastasis. The 3-year OS, DFS and stoma–free rates were 89.5%, 65.5%, and 78.1% respectively.

Conclusion

SCRT followed by oxaliplatin-based consolidation chemotherapy is safe and effective for tumor downstaging in LARC, further improving the sphincter preservation rate.

Available only for authorised users

Sung H, Ferlay J, Siegel R et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Siegel RL, Miller KD, Sauer AG et al (2020) Colorectal cancer statistics, 2020. Ca Cancer J Clin 70:145–164. https://doi.org/10.3322/caac.21601CrossRefPubMed

Keller DS, Berho M, Perez R et al (2020) The multidisciplinary management of rectal cancer. Nat Rev Gastroentero 17:414–429. https://doi.org/10.1038/s41575-020-0275-yCrossRef

IV AA, Koprowski MA, Nabavizadeh N, Tsikitis VL (2022) The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation. Ann Gastroenterol 35:226–233. https://doi.org/10.20524/aog.2022.0712

Guida AM, Sensi B, Formica V et al (2022) Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. Biol Direct 17:16. https://doi.org/10.1186/s13062-022-00329-7CrossRefPubMedPubMedCentral

Kasi A, Abbasi S, Handa S et al (2020) Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer. Jama Netw Open 3:e2030097. https://doi.org/10.1001/jamanetworkopen.2020.30097

Liao CK, Kuo YT, Lin YC et al (2022) Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol 29:3708–3727. https://doi.org/10.3390/curroncol29050297CrossRefPubMedPubMedCentral

Rödel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696. https://doi.org/10.1200/jco.2005.02.1329

George TJ, Allegra CJ, Yothers G (2015) Neoadjuvant rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trials. Curr Colorectal Cancer Rep 11:275–280. https://doi.org/10.1007/s11888-015-0285-2

10.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications. Ann Surg 240:205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae

11.

Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Brit J Surg 93:1215–1223. https://doi.org/10.1002/bjs.5506CrossRefPubMed

12.

Ngan SY, Burmeister B, Fisher RJ et al (2012) Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with t3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol 30:3827–3833. https://doi.org/10.1200/jco.2012.42.9597CrossRefPubMed

13.

Pettersson D, Cedermark B, Holm T et al (2010) Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Brit J Surg 97:580–587. https://doi.org/10.1002/bjs.6914CrossRefPubMed

14.

Pettersson D, Lörinc E, Holm T et al (2015) Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg 102:972–978. https://doi.org/10.1002/bjs.9811CrossRefPubMed

15.

Erlandsson J, Holm T, Pettersson D et al (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18:336–346. https://doi.org/10.1016/s1470-2045(17)30086-4CrossRefPubMed

16.

van der Valk MJM, Marijnen CAM, van Etten B et al (2020) Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. Radiother Oncol 147:75–83. https://doi.org/10.1016/j.radonc.2020.03.011CrossRefPubMed

17.

Jin J, Tang Y, Hu C et al (2022) Multicenter, randomized, Phase III Trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol JCO2101667. https://doi.org/10.1200/jco.21.01667

18.

Thavaneswaran S, Kok PS, Price T (2017) Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. Expert Rev Anticanc 17:965–979. https://doi.org/10.1080/14737140.2017.1369881CrossRef

19.

Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29–42. https://doi.org/10.1016/s1470-2045(20)30555-6CrossRefPubMed

20.

Chakrabarti D, Rajan S, Akhtar N et al (2021) Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. Brit J Surg 108:znab020. https://doi.org/10.1093/bjs/znab020

21.

Markovina S, Youssef F, Roy A et al (2017) Improved metastasis- and disease-free survival with preoperative sequential short-course radiation therapy and FOLFOX chemotherapy for rectal cancer compared with neoadjuvant long-course chemoradiotherapy: results of a matched pair analysis. Int J Radiat Oncol Biology Phys 99:417–426. https://doi.org/10.1016/j.ijrobp.2017.05.048CrossRef

22.

Ciseł B, Pietrzak L, Michalski W et al (2019) Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. Ann Oncol 30:1298–1303. https://doi.org/10.1093/annonc/mdz186CrossRefPubMed

23.

Chapman WC, Kim H, Bauer P et al (2022) Total neoadjuvant therapy with short-course radiation: us experience of a neoadjuvant rectal cancer therapy. Dis Colon Rectum 65:198–206. https://doi.org/10.1097/dcr.0000000000001997CrossRefPubMed

24.

Garcia-Aguilar J, Patil S, Gollub MJ et al (2022) Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 40:2546–2556. https://doi.org/10.1200/jco.22.00032CrossRefPubMedPubMedCentral

25.

Chin R-I, Roy A, Pedersen KS et al (2022) Clinical complete response in patients with rectal adenocarcinoma treated with short-course radiation therapy and non-operative management. Int J Radiat Oncol Biology Phys 112:715–725. https://doi.org/10.1016/j.ijrobp.2021.10.004CrossRef

26.

Bahadoer R, Dijkstra E (2022) Patterns of locoregional failure and distant metastases in patients treated for locally advanced rectal cancer in the RAPIDO trial. Eur J Surg Oncol 48:e34. https://doi.org/10.1016/j.ejso.2021.12.439

27.

Conroy T, Bosset JF, Etienne PL et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702–715. https://doi.org/10.1016/s1470-2045(21)00079-6CrossRefPubMed

28.

Fokas E, Schlenska-Lange A, Polat B et al (2022) Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer. Jama Oncol 8:e215445. https://doi.org/10.1001/jamaoncol.2021.5445

29.

ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/ct2/show/NCT05253846. Accessed on 6 Jan 2023

30.

ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04246684. Accessed on 6 Jan 2023

31.

Fokas E, Fietkau R, Hartmann A et al (2018) Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol 29:1521–1527. https://doi.org/10.1093/annonc/mdy143CrossRefPubMed

32.

Huang WS, Kuan FC, Lin MH et al (2020) Prognostic significance of neoadjuvant rectal scores in preoperative short-course radiotherapy and long-course concurrent chemoradiotherapy for patients with locally advanced rectal cancer. Ann Surg Oncol 27:4309–4318. https://doi.org/10.1245/s10434-020-09018-zCrossRefPubMed

33.

Lim YJ, Song C, Jeon SH et al (2021) Risk stratification using neoadjuvant rectal score in the era of neoadjuvant chemoradiotherapy: validation with long-term outcome data. Dis Colon Rectum 64:60–70. https://doi.org/10.1097/dcr.0000000000001777CrossRefPubMed

34.

Dijkstra EA, Nilsson PJ, Hospers GAP et al (2023) Locoregional Failure During and After Short-course Radiotherapy followed by Chemotherapy and Surgery Compared to Long-course Chemoradiotherapy and Surgery - A Five-year Follow-up of the RAPIDO Trial [published online ahead of print, 2023 Jan 20]. Ann Surg. https://doi.org/10.1097/SLA.0000000000005799

35.

Romesser PB, Park BK, Nemirovsky D et al (2023) Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. J Clin Oncol 41:10–10. https://doi.org/10.1200/jco.2023.41.4_suppl.10CrossRef

36.

Glynne-Jones R, Hollingshead J (2023) TNT and local recurrence in the RAPIDO trial — untangling the puzzle. Nat Rev Clin Oncol 1–2. https://doi.org/10.1038/s41571-023-00751-4

Title: Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer
Authors: Chun-Kai Liao
Ya-Ting Kuo
Yu-Jen Hsu
Yih-Jong Chern
Yen-Lin Yu
Yueh-Chen Lin
Pao-Shiu Hsieh
Jy-Ming Chiang
Chien‐Yuh Yeh
Jeng-Fu You
Publication date: 01-12-2023
Publisher: Springer Berlin Heidelberg
Keywords: Rectal Cancer
Rectal Cancer
Enterostomy
Enterostomy
Radiotherapy
Cytostatic Therapy
Published in: International Journal of Colorectal Disease / Issue 1/2023
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-023-04388-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Discussion on the benefits of different treatment strategies in elderly and non-elderly patients with appendix MiNEN: a retrospective study based on SEER database

Challenges in the interdisciplinary treatment of leakages after left-sided colorectal surgery: endoscopic negative pressure therapy, open-pore film drainage therapy and beyond

Retrospective study of sacral neuromodulator implantations in a French hospital center: Lifespan and hospital costs assessment

Use of lymph node ratio to guide clinical decision-making concerning adjuvant radiotherapy in pT1-2N1 rectal cancer

Underwater versus conventional endoscopic mucosal resection for colorectal lesions: a systematic review and meta-analysis of randomized clinical trials

A prognostic score based on B cell and plasma cell densities compared to T cell densities in colorectal cancer